The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development

The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domai...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Nan, Zhang, Yun, Zhang, Jin-Chun, Feng, Ling, Bao, Jin-Ku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier (Singapore) Pte Ltd. 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127315/
https://www.ncbi.nlm.nih.gov/pubmed/24342026
http://dx.doi.org/10.1016/j.jfma.2013.11.006
Descripción
Sumario:The newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV) is becoming another “SARS-like” threat to the world. It has an extremely high death rate (∼50%) as there is no vaccine or efficient therapeutics. The identification of the structures of both the MERS-CoV receptor binding domain (RBD) and its complex with dipeptidyl peptidase 4 (DPP4), raises the hope of alleviating this currently severe situation. In this review, we examined the molecular basis of the RBD-receptor interaction to outline why/how could we use MERS-CoV RBD to develop vaccines and antiviral drugs.

Ejemplares similares